Woman in Chains32 schreef op 5 december 2019 13:19:
[...]
Validatie window eraf halen...? Sanderus kan dit wellicht verder duiden.
EUROPEAN MEDICINES AGENCY
VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Foster City, Calif. and Mechelen, Belgium – August 15, 2019 22.01 CET – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA)
has been validated and is now under evaluation by the European Medicines Agency (EMA).